Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check42 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new collaborators and a revision number, while key details about the clinical trial for thymic carcinoma have been removed, including specific study protocols and inclusion/exclusion criteria.SummaryDifference47%
- Check49 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check92 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check107 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check114 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.